



10 November 2021

**LungLife AI, Inc.**  
("LungLife" or the "Company")

**Block Listing Application**

LungLife AI (AIM: LLA1), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the "**Block Admission**") has been made to the London Stock Exchange for up to 1,356,139 common shares of US \$0.0001 each (the "**Block Listing Shares**") to be admitted to trading on AIM ("**Admission**").

The common shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options and vested awards pursuant to the terms of the following share plans (the "**Schemes**"):

<b>Scheme</b>	<b>No. of common shares under block listing application</b>
2010 Stock Incentive Plan	480,775
2020 Stock Incentive Plan	201,374
2021 Omnibus Long-Term Incentive Plan	673,990

The Block Listing Shares will, upon issue, rank equally with all other common shares of US \$0.0001 each in the capital of the Company that are then in issue. The Block Listing Admission is expected to become effective on 15 November 2021.

**For further information please contact:**

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
Via Walbrook PR

**Investec Bank plc (Nominated Adviser & Broker)**  
Daniel Adams / Virginia Bull / Cameron MacRitchie

Tel: +44 (0)20 7597 5970

**Walbrook PR Limited**  
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or [LungLifeAI@walbrookpr.com](mailto:LungLifeAI@walbrookpr.com)  
Mob: 07980 541 893 / 07407 804 654